DUBLIN--(BUSINESS WIRE)--The "Global Pharmacovigilance Market - Forecasts From 2018 to 2023" report has been added to ResearchAndMarkets.com's offering.
The global Pharmacovigilance market is expected to reach US$6.705 billion by 2023 from US$3.224 billion in 2017 growing at a CAGR of 12.98%.
The market is expected to show significant growth during the forecast period owing to the rising drug development and number of drugs under investigation. Rising incidences of the adverse drug reaction coupled with stringent government regulations to monitor them have also boosted the market for pharmacovigilance.
However, lack of patient data security and safety might hamper the growth of the pharmacovigilance market during the given time frame. Adopting a global approach for pharmacovigilance assessment has also been a major challenge for the pharmacovigilance industry.
Major industry players profiled as part of the report are Cognizant, Bioclinica and Kinapse among others.
Key Topics Covered
1. Introduction
2. Research Methodology
3. Key Findings of the Study
4. Market Dynamics
5. Global Pharmacovigilance Market Forecast by Clinical Trial Phase
6. Global Pharmacovigilance Market Forecast by Service Provider
7. Global Pharmacovigilance Market Forecast by End-Users
8. Global Pharmacovigilance Market Forecast by Geography
9. Competitive Intelligence
10. Company Profiles
- Eli Lilly and Company
- Cognizant
- Kinapse (A Syneos Health Company)
- Sciformix (A Covance Company)
- Quintiles IMS
- Pharmaceutical Product Development LLC
- Oviya MedSafe
- APCER Life Sciences Inc.
- Navitas Life Sciences
- Bioclinica
For more information about this report visit https://www.researchandmarkets.com/research/h2nvwg/global?w=4
